‘Rise in the incidence of fast paced lifestyle conditions such as Diabetes will continue to drive the growth of the Insulin delivery device industry, says RNCOS.

Noida, UP -- (SBWire) -- 12/26/2014 --Increasing stress and the fast pace of modern life are taking their toll on people. One of the direct consequences is the rise of lifestyle diseases. Lifestyle diseases, by definition, are health problems that are directly related to changes in one's way of living. They include asthma, cardiac conditions, cancer, osteoporosis, and kidney failure, among other things.

Lifestyle-related health conditions like diabetes, hypertension and cholesterol complicate matters further and increase the risk of lifestyle diseases.

According to International Diabetes Federation there were 382 Million people living with Diabetes in 2013. The majority of this population was aged between 40 and 59, and 80% of them have been living in low and middle-income countries. It is estimated that the number of people living with diabetes will increase by 55%, making a total of 552 Million cases by 2030. With the continuous rise in both diabetes Type-1 and diabetes Type-2, there is an urge for the rapid medication in the form of insulin. Thus, rising number of cases will propel the growth of latest technologies, such as including pens, injectors, pumps, and sprays.

The report "Global Insulin Delivery Devices Market Outlook 2018" is spread in over 115 pages and provides an in-depth research and rational analysis of the current status and future prospect of the insulin delivery systems market. The study presents a global picture about the prevalence of diabetes and the overall market for insulin delivery systems. It includes a geographical analysis of insulin delivery systems in key diabetic countries. The research further covers the market for main insulin delivery systems along with their current and future projections. RNCOS' study leads to the proposition that innovation has huge scope in this field and we have explored and provided information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche, and Becton Dickenson and Company, which together account for more than 90% of the global market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM723.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.